Analysis of drug prescription appropriateness according to the STOPP/START criteria of the elderly patients with type 2 diabetes mellitus in the endocrinology department of a multi-speciality hospital

To assess the appropriateness of prescribed drugs according to the STOPP/START criteria of elderly patients with type 2 diabetes mellitus (T2DM) in the endocrinology department of a multi-speciality hospital.

Medical records of 136 patients ≥65 years old with T2DM hospitalized in the endocrinology department of  the multi-speciality hospital (Moscow, Russia) were analyzed according to  the «STOPP/START» criteria.

The analysis of  prescription leaflets has identified 30 potentially not recommended drugs (46 patients [33,8%]), the use of which should be avoided in certain clinical situations. Also the analysis has identified 175 medications that should be considered for elderly patients with certain conditions (89 patients [65,4%]). The most frequent identified STOPP criteria were: «Glibenclamide or chlorpropamide or glimepiride with T2DM» (23,3%); «Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer disease or gastro-intestinal bleeding, unless with concurrent histamine H2 receptor antagonist, proton pump inhibitors or misoprostol» (13,3%) and «NSAID with estimated glomerular filtration rate 20–50 ml/min/1.73m2» (3%). The most frequent START criteria were: «Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, where the patient’s functional status remains independent for activities of daily living and life expectancy is >5 years» (25,1%); «Сlopidogrel with a documented history of cerebral or peripheral vascular disease» (18,9%); «Aspirin with a documented history of atherosclerotic coronary disease in patients with sinus rhythm» (18,3%).

In  patients ≥ 65 years old with T2DM potentially not recommended drugs are often administrated and there are no prescriptions for some appropriate drugs required in certain clinical settings. The findings give evidence of the need to optimization of pharmacotherapy in elderly and senile patients with T2DM. This adaptation will improve the patients’ quality of  life and avoid wasteful spending.

1. Россия в цифрах. 2018 : краткий статистический сборник / Росстат. М., 2018. 255 с.

2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Diabetes mellitus in the Russian Federation: prevalence, incidence, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018; 21(3):144–59. DOI: 10.14341/ DM9686. (In Russ.)

3. Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boytsov S.A., Boldueva S.A., Garganeeva N.P., Doshchitsin V.L., Karateev A.E., Kotovskaya Y.V., Lila A.M., Lukyanov M.M., Morozova T.E., Pereverzev A.P., Petrova M.M., Pozdnyakov Y.M., Syrov A.V., Tarasov A.V., Tkacheva O.N., Shalnova S.A. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2017; 16(6):5–56. DOI: 10.15829/1728-8800-2017-6-5-56. (In Russ.)

4. Sychev D.A. Polypharmacy in clinical practice: a problem and solutions. 2nd edition. St. Petersburg: CSC «Profession»; 2018. 272 p. (In Russ)

5. Gallagher P.F., O'Connor M.N., O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011; 89(6): 845–54. DOI: 10.1038/clpt.2011.44.

6. Cahir C., Bennett K., Teljeur C., Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. 2014 Jan; 77(1):201-10. Br J Clin Pharmacol. 2014; 77(1): 201-10. DOI: 10.1111/bcp.12161.

7. Davies E.A., O’Mahony M.S. Adverse drug reactions in special populations — the elderly. Br J Clin Pharmacol. 2015; 80(4): 796–807. Br J Clin Pharmacol. 2015; 80(4): 796–807. DOI: 10.1111/bcp.12596.

8. Hamilton H., Gallagher P., Ryan C., Byrne S., O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–19. DOI: 10.1001/ archinternmed.2011.215.

9. O'Connor M.N. Adverse Drug Reactions in Older People During Hospitalisation: Prevalence, Risk factors and Recognition: unpublished MD thesis. Ireland: University College Cork, 2013.

10. Fick D., Semla T., Beizer J., Brandt N., Dombrowski R., DuBeau CE, Flanagan N., Hanlon J., Hollmann P., Linnebur S., Nau D., Rehm B., Sandhu S., Steinman M.. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2012; 60(4): 616–631. DOI: 10.1111/j.1532–5415.2012.03923.x.

11. Curtain C.M., Bindoff I.K., Westbury J.L., Peterson G.M. A comparison of prescribing criteria when applied to older community-based patients. Drugs Aging. 2013; 30(11):935–43. DOI: 10.1007/ s40266-013-0116-6.

12. Murad M., Coto-Yglesias F., Wang A., Sheidaee N., Mullan R., Elamin M., Erwin P., Montori V. Druginduced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009; 94(3):741-5. DOI: 10.1210/ jc.2008–1416.

13. Sharonova L.A., Verbovoy A.F., Kosareva O.V. The role of sulfonylures in the treatment of type 2 diabetes. Diabetes Mellitus. 2016; 19(3): 2218. DOI:10.14341/DM2003422-27. (In Russ.)

14. RLS: Pharmacological group — Hypoglycemic synthetic and other drugs. Available at: https://www.rlsnet.ru/fg_index_id_292.htm Accessed May 3, 2019. (In Russ.)

15. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389–94. DOI: 10.2337/dc06-1789.

16. Janashia P.Kh., Mirina E.Yu. Principle of Management of Type 2 Diabetes. RMJ. 2005; 26:1761-1766. (In Russ.)

17. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32(1):193– 203. DOI: 10.2337/dc08-9025.

18. Pedersen T.R., Wilhelmsen L., Faergeman O., Strandberg T.E., Thorgeirsson G., Troedsson L., Kristianson J., Berg K., Cook T.J., Haghfelt T., Kjekshus J., Miettinen T., Olsson A.G., Pyörälä K., Wedel H. The Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383–9. DOI: org/10.1016/ S0140-6736(94)90566-5.

19. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole Th.G., Brown L., Warnica J.W., Arnold J.M.O., Wun Ch., Davis B.R., Braunwald E. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med. 1996; 335(14):1001– 9. DOI: 10.1056/NEJM199610033351401.

20. LaRosa J.C., Grundy S.M., Waters D.D., Shear Ch., Barter Ph., Fruchart J., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., Wenger N.K. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med. 2005; 352(14):1425–35. DOI: 10.1056/NEJMoa050461.

21. Collins R., Armitage J., Parish S., Sleight P., Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7–22. DOI:10.1016/ S0140-6736(02)09327-3.

22. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364):1149–58. DOI:10.1016/ S0140-6736(03)12948-0.

23. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet. 2004; 364(9435):685-96. DOI:10.1016/S0140-6736(04)16895-5.

24. Silverman M.G., Ference B.A., Im K., Wiviott S.D., Giugliano R.P., Grundy S.M., Braunwald E., Sabatine M.S. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316(12):1289–97. DOI: 10.1001/jama.2016.13985.

25. Harker L.A., Boissel J.P., Pilgrim A.J., Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999; 21(4):325–35. DOI: 10.2165/00002018-199921040-00007.

26. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., FabryRibaudo L., Hu T., Topol E.J., Fox K.A.; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49(19):1982–8. DOI:10.1016/j.jacc.2007.03.025

27. Wang T.H., Bhatt D.L., Fox K.A., Steinhubl S.R., Brennan D.M., Hacke W., Mak K.H., Pearson T.A., Boden W.E., Steg P.G., Flather M.D., Montalescot G., Topol E.J.; CHARISMA Investigators. An analysis of mortality rates with dual–antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007; 28(18):2200–7. DOI:10.1093/ eurheartj/ehm274.

28. Sudlow C.L., Mason G., Maurice J.B., Wedderburn C.J., Hankey G.J. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009; (4):CD001246. DOI: 10.1002/14651858.CD001246. pub2.

29. Robless P., Mikhailidis D.P., Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001; 88(6):787–800. DOI:10.1046/j.0007-1323.2001.01774.x

30. Girolami B., Bernardi E., Prins M.H., ten Cate J.W., Prandoni P., Hettiarachchi R., Marras E., Stefani P.M., Girolami A., Büller H.R. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta–analysis. Thromb Haemost. 1999; 81(5):715–22. DOI: 10.1055/s-0037-1614560

31. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J.S., Marx N., Opie L.H., Pfisterer M., Prescott E., Ruschitzka F., Sabaté M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. DOI: 10.1093/ eurheartj/eht296.

32. Lewis H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman Th.C., Doherty J.E. III, Schnaper H.W., LeWinter M.M., Linares E., Pouget J.M., Sabharwal S.C., Chesler E., DeMots H. Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina — Results of a Veterans Administration Cooperative Study. The New England Journal of Medicine. 1983. 309(7):396– 403. DOI: 10.1056/NEJM198308183090703

33. Wallentin L. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336:827–30. DOI:10.1016/0140-6736(90)92336-G.

34. Baigent C., Collins R., Appleby P., Parish S., Sleight P., Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998; 316(7141):1337–43. DOI:10.1136/bmj.316.7141.1337.

35. Shestakova M.V., Shamkhalova M.Sh., YarekMartynova I.Ya., Sukhareva O. Yu., Vikulova О.К., Martynov S.A., Klefortova I.I., Trubitsyna N.P., Zaitseva N.V., Tarasov E. V. Сlinical guidelines for the diagnosis, screening, prevention and treatment of chronic kidney disease in patients with diabetes mellitus. Moscow. 2014. 39p. Available at: https://minzdrav. gov-murman.ru/documents/poryadki-okazaniyameditsinskoy-pomoshchi/pohki.pdf Accessed May 3, 2019. (In Russ.)

36. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H., Heidbuchel H., Hendriks J., Hindricks G., Manolis A.S., Oldgren J., Popescu B.A., Schotten U., Putte B.V., Vardas P.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. DOI: 10.1093/eurheartj/ ehw210.

37. Talajic M., Khairy P., Levesque S., Connolly S.J., Dorian P., Dubuc M., Guerra P.G., Hohnloser S.H., Lee K.L., Macle L., Nattel S., Pedersen O.D., Stevenson L.W., Thibault B., Waldo A.L., Wyse D.G., Roy D.; AFCHF Investigators. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;55(17):1796–802. DOI: 10.1016/j.jacc.2010.01.023.